NHNancy L. Heard-Costa

Nancy L. Heard-Costa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nancy L. Heard-Costa has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corrigendum to Genetic modification of inflammation- and clonal hematopoiesis–associated cardiovascular risk

    by Zhi Yu, Trevor P. Fidler, Yunfeng Ruan, Caitlyn Vlasschaert, Tetsushi Nakao, Md Mesbah Uddin, Taralynn Mack, Abhishek Niroula, J. Brett Heimlich, Seyedeh M. Zekavat, et al.

  • Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed

    by Peter Orchard, Thomas W Blackwell, Linda Kachuri, Peter J Castaldi, Michael H Cho, Stephanie A Christenson, Peter Durda, Stacey Gabriel, Craig P Hersh, Scott Huntsman, et al.

    Most genetic variants associated with complex traits are hypothesized to regulate gene expression. To understand the genetics underlying gene expression variability, we characterized 14,324 RNA-sequencing samples from the Trans-Omics for Precision Medicine program and performed expression and splicing quantitative trait locus (e/sQTL) analyses in six tissues and cell types, including whole blood ( n = 6454) and lung ( n = 1291). We detected tens of thousands of secondary cis-e/sQTLs, showing that secondary cis-e/sQTL discovery remains unsaturated. We fine-mapped UK Biobank–derived genome-wide association study (GWAS) signals from 164 traits and identified e/sQTL colocalizations for 10,611 GWAS signals, including 7096 that colocalize with secondary e/sQTLs. Our results suggest that even larger e/sQTL analyses will uncover additional secondary e/sQTLs, further benefiting GWAS interpretation.


  • Open Access

    Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk

    by Kara M. Barnao, Aubrey K. Hubbard, Irenaeus C. C. Chan, Weiyin Zhou, Yasminka A. Jakubek, Giulio Genovese, Wendy S. W. Wong, Rebecca L. Kelly, Corey D. Young, Derek W. Brown, et al.

    Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are two types of clonal hematopoiesis (CH) associated with hematological parameters and malignancy risk. Here we show, in genomic data from 546,090 biobank participants, that co-occurring CH (≥2 CH mutations detected) is present in 1.6% of cancer-free individuals and shows strong evidence for selection (up to 804x enrichment). Co-occurrence is more frequent in those with a prior cancer (3.6%), suggesting treatment-induced selection. Acquisition of CHIP usually precedes mCAs with co-occurrences manifesting stronger phenotypic disruptions in telomere attrition and hematologic parameters than component CH events. Individuals with co-occurring CH have pronounced elevations in risk of myeloid and lymphoid malignancies (HRs>40), particularly when CHIP and mCAs overlap genomically. Our findings indicate CH co-occurrences are selected for in the aging population and identify CH clones with notable implications for future malignancy risk.


  • Open Access

    An integrated germline and somatic genomic model for coronary artery disease

    by Xiong Yang, Min Seo Kim, Xinyu Zhu, Mesbah Uddin, Tetsushi Nakao, So Mi Jemma Cho, Satoshi Koyama, Tingfeng Xu, Laurens F. Reeskamp, Rufan Zhang, et al.

    Multiple germline and somatic genomic factors are associated with risk of coronary artery disease, but there is no single measure of risk that integrates all information from a DNA sample. To address this gap, we develop an integrated genomic model that includes six germline and somatic genetic drivers for coronary artery disease, including polygenic risk score, genetically-proxied proteomic/metabolomic risk scores, and clonal hematopoiesis of indeterminate potential. We evaluated its predictive power in the UK Biobank (N = 391,536), and validate it using data from the TOPMed program (N = 34,177). The 10-year coronary artery disease risk based on the integrated genomic model profile ranges from 1.1% to 15.5% in the UK Biobank and from 3.8% to 33.0% in TOPMed, with a more pronounced gradient in males than females. The integrated genomic model captures the cumulative effect of multiple genetic drivers, identifying individuals at high risk for coronary artery disease despite lacking any single high-risk genetic factor, as well as individuals at low risk despite carrying known high-risk factors. In middle age, the integrated genomic model augments the performance of the Pooled Cohort Equations, a clinical risk calculator for coronary artery disease. While the integrated genomic model yields only modest incremental predictive value over polygenic risk score at the population level, it identifies approximately 13% of high-risk individuals not detected by polygenic risk score alone.


  • Open Access

    Hearing loss in the young-old is associated with increased risk for Alzheimer's disease and vascular dementia

    by Lily Francis, Alexa Beiser, Sophia Lu, Sharon G Kujawa, Nancy Heard-Costa, Francis B Kolo, M Ilyas Kamboh, Rebecca Bernal, D Bradley Welling, Richard L Alcabes, et al.

    Hearing loss is a risk factor for dementia, but dementia subtypes underlying this association and effect modifiers are unknown. Using data collected from 2000 Framingham Heart Study participants we found that hearing loss increases risk for Alzheimer's disease and vascular dementia in participants aged 60–70 years (“young-old”) at time of hearing assessment (Alzheimer's disease: HR 1.46[CI 1.07–2.0] p = 0.017; vascular dementia: HR 2.08[CI 1.22–3.56] p = 0.007). Longer duration of hearing loss determines increased risk for Alzheimer's disease and vascular dementia, and screening and intervention for hearing loss from mid-life may help reduce dementia.


  • cellSTAAR: incorporating single-cell-sequencing-based functional data to boost power in rare variant association testing of noncoding regions

    by Eric Van Buren, Yi Zhang, Xihao Li, Margaret Sunitha Selvaraj, Zilin Li, Hufeng Zhou, Nicholette D. Palmer, Donna K. Arnett, John Blangero, Eric Boerwinkle, et al.

    Understanding how rare genetic variants influence complex traits remains a major challenge, particularly when these variants lie in noncoding regions of the genome. The effects of variants within candidate cis-regulatory elements (cCREs) often depend on the cell type, making interpretation difficult. Here we introduce cellSTAAR, which integrates whole-genome sequencing data with single-cell assay for transposase-accessible chromatin using sequencing data to capture variability in chromatin accessibility across cell types via the construction of cell-type-specific functional annotations and regulatory elements. To reflect the uncertainty in cCRE–gene linking, cellSTAAR uses a comprehensive strategy to link cCREs to their target genes. We applied cellSTAAR to data from the Trans-Omics for Precision Medicine consortium (n ≈ 60,000) and replicated our findings using the UK Biobank (n ≈ 190,000). Across four lipid traits, cellSTAAR improved the detection of biologically meaningful associations and enhanced biological interpretability. These results demonstrate the potential of cell-type-aware approaches to boost discovery in rare variant whole-genome sequencing association studies.


  • Open Access

    Integrating whole genome and transcriptome sequencing to characterize the genetic architecture of isoform variation

    by Chunyu Liu, Roby Joehanes, Jiantao Ma, Jiuyong Xie, Jian Yang, Mengyao Wang, Tianxiao Huan, Shih-Jen Hwang, Jia Wen, Quan Sun, et al.

    We present a whole-blood isoform ratio QTL (irQTL) resource by analyzing genome-wide isoform-to-gene expression ratios using sequencing data. In Framingham Heart Study (FHS, n = 2622) discovery, we identify over 1.1 million cis -irQTLs (minor allele frequency [MAF] ≥ 0.01, ±1 Mb of 10,883 isoform transcripts, P < 5 × 10 −8 ) across 4,971 genes. Among 11,425 sentinel cis -irQTLs, 72% replicate ( P < 1 × 10 −4 ) in the Women’s Health Initiative (WHI; n = 2005). Notably, 20% of cis -irQTLs have no significant association with overall gene expression, indicating isoform-specific regulation. These variants are enriched at splice donor/acceptor sites and genome-wide association study loci ( P < 1 × 10 −10 ). We also identify 1870 sentinel trans -irQTLs (MAF ≥ 0.01, P < 1.5 × 10 −13 ) for 1,084 isoforms across 590 genes, and 2327 rare cis -irQTLs (0.003 < MAF < 0.01) for 2467 isoforms of 1428 genes in FHS, with external replication rates of 61% and 41% in WHI, respectively. We highlight rs12898397 in ULK3 , which alters splice site usage and reduces expression of a full-length isoform. Mendelian randomization supports a causal role between this isoform shift and reduced diastolic blood pressure. These findings highlight the power of irQTL mapping to uncover transcript-specific regulatory mechanisms underlying complex traits.


  • Open Access

    Integrating genetic and transcriptomic data to identify genes underlying obesity risk loci

    by Hanfei Xu, Shreyash Gupta, Ian Dinsmore, Abbey Kollu, Anne Marie Cawley, Mohammad Y. Anwar, Hung-Hsin Chen, Lauren E. Petty, Sudha Seshadri, Misa Graff, et al.

    Background: Genome-wide association studies (GWAS) have identified numerous body mass index (BMI) loci. However, most underlying mechanisms from risk locus to BMI remain unknown. Leveraging omics data through integrative analyses could provide more comprehensive views of biological pathways on BMI. Methods: We analyzed genotype and blood gene expression data from up to 5619 samples in the Framingham Heart Study (FHS). Using 3992 single-nucleotide polymorphisms (SNPs) at 97 BMI loci and 1408 transcripts within 1 Mb, we performed separate association analyses of transcript with BMI and SNP with transcript ( P BMI and P SNP , respectively) and then a correlated meta-analysis between the full summary data sets ( P META ). Transcripts were prioritized if we identified transcripts that met Bonferroni-corrected significance within each omic, showed stronger associations in the correlated meta-analysis than each omic, and had corresponding SNPs in the SNP-transcript-BMI association that were at least nominally associated with BMI in FHS data. We tested for generalization of identified association in a Hispanic ancestry sample of blood gene expression data and other samples in hypothalamus, nucleus accumbens, liver, and visceral adipose tissue (VAT) with significant threshold: P META < 0.05 & P META < P SNP & P META < P BMI . Results: Among 308 significant SNP-transcript-BMI associations, we identified seven genes ( NT5C2 , GSTM3 , SNAPC3 , SPNS1 , TMEM245 , YPEL3 , and ZNF646 ) in five association regions. We generalized results for SNAPC3 and YPEL3 in Hispanic ancestry sample, for YPEL3 in the nucleus accumbens, ZNF646 and GSTM3 in VAT, and NT5C2 , SNAPC3 , TMEM245 , YPEL3 , and ZNF646 in liver. Conclusion: The identified genes help link the genetic variation at obesity-risk loci to biological mechanisms and health outcomes, thus translating GWAS findings to function.


  • DNA Methylation Signatures of Cardiovascular Health Provide Insights Into Diseases

    by Madeleine Carbonneau, Yi Li, Yishu Qu, Yinan Zheng, Alexis C. Wood, Mengyao Wang, Chunyu Liu, Tianxiao Huan, Roby Joehanes, Xiuqing Guo, et al.

    BACKGROUND: The association of overall cardiovascular health (CVH) with changes in DNA methylation (DNAm) has not been well characterized. METHODS: We calculated the American Heart Association’s Life’s Essential 8 score to reflect CVH in 5 cohorts with diverse backgrounds (mean age 54 years, 55% women, and enrollment year ranging from 1989 to 2012). Epigenome-wide association studies (EWAS) for Life’s Essential 8 score were conducted, followed by bioinformatic analyses. DNAm loci significantly associated with Life’s Essential 8 score were used to calculate a CVH DNAm score. We examined the association of the CVH DNAm score with incident cardiovascular disease (CVD), cardiovascular disease–specific mortality, and all-cause mortality. RESULTS: We identified 609 cytosine-phosphate-guanines (CpGs) associated with Life’s Essential 8 score at false discovery rateP P =2.4e−15) and 21-fold for ischemic heart disease ( P =7.4e−38). Two-sample Mendelian randomization (MR) analysis showed significant association between 141 CpGs and ten phenotypes (261 CpG-phenotype pairs) at false discovery rateMIR33B [microRNA 33b] and SREBF1 [sterol regulatory element–binding transcription factor 1]) is associated with a lower risk of stroke ( P =8.1e−6). In multivariable prospective analyses, the CVH DNAm score was consistently associated with clinical outcomes across participating cohorts. Per SD increase in the CVH DNAm score, the decrease in risk of incident cardiovascular disease, cardiovascular disease mortality, and all-cause mortality ranged from 19% to 32%, 28% to 40%, and 27% to 45%, respectively. CONCLUSIONS: We identified new DNAm signatures for CVH across diverse cohorts. Our analyses indicate that multiple biological pathways may be relevant to the observed association between CVH and clinical outcomes.


  • Open Access

    Epigenome-wide DNA methylation association study of CHIP provides insight into perturbed gene regulation

    by Sara Kirmani, Tianxiao Huan, Joseph C. Van Amburg, Roby Joehanes, Mesbah Uddin, Ngoc Quynh H. Nguyen, Bing Yu, Jennifer A. Brody, Myriam Fornage, Jan Bressler, et al.

    With age, hematopoietic stem cells can acquire somatic mutations in leukemogenic genes that confer a proliferative advantage in a phenomenon termed CHIP. How these mutations result in increased risk for numerous age-related diseases remains poorly understood. We conduct a multiracial meta-analysis of EWAS of CHIP in the Framingham Heart Study, Jackson Heart Study, Cardiovascular Health Study, and Atherosclerosis Risk in Communities cohorts (N = 8196) to elucidate the molecular mechanisms underlying CHIP and illuminate how these changes influence cardiovascular disease risk. We functionally validate the EWAS findings using human hematopoietic stem cell models of CHIP. We then use expression quantitative trait methylation analysis to identify transcriptomic changes associated with CHIP-associated CpGs. Causal inference analyses reveal 261 CHIP-associated CpGs associated with cardiovascular traits and all-cause mortality (FDR adjusted p-value < 0.05). Taken together, our study reports the epigenetic changes impacted by CHIP and their associations with age-related disease outcomes.